Trabeculectomy and MMC a success at nine years

Article

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

Patients with POAG, uncontrolled by therapy, who took part in a prospective, randomized, double-blind clinical trial between 1995 and 1999 were reviewed. Subjects originally underwent a trabeculectomy with MMC or saline solution and cases with >9 years follow-up were considered for review.

Of the 133 eyes included in the study, 94 had a >9 years follow-up (57 treated with MMC and 37 with placebo). An IOP of <14 mmHg was found in 47 and 17 eyes, respectively, six and 11 eyes, respectively were taking medical therapy, while four and nine eyes had undergone a re-operation. Glaucomatous visual field progression was noted in five and 16 eyes however, no significant difference was seen in incidence of cataract and other complications.

These nine-year results suggest that trabeculectomy with MMC and intensive postoperative management can significantly improve success rates and decrease the incidence of complications.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.